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Abstract. Epidermal growth factor (EGF) is overexpressed in 
many cancers and is associated with worse prognosis. EGF 
binds to its cell surface receptor (EGFR), which induces 
EGFR phosphorylation. Phosphorylated EGFR (p-EGFR) 
is translocated into the nucleus, which increases cancer cell 
activity. Nicotine, which is one of the main components of 
tobacco, is absorbed through pulmonary alveoli and mucosal 
epithelia in the head and neck region by smoking and moves 
into the blood. Nicotine in blood binds to nicotinic acetyl-
choline receptor (nAChR) in the central nervous system and 
serves a crucial role in tobacco addiction. Although nAChR 
localization is thought to be limited in the nervous system, 
nAChR is present in a wide variety of non-neuronal cells, 
including cancer cells. Recent studies suggest that nicotine 
contributes to the metastasis and resistance to anti-cancer 
drugs of various cancer cells. However, it remains unknown 
whether head and neck squamous cell carcinoma (HNSCC) 
cells can utilize nicotine-nAChR signaling to metastasize 
and acquire resistance to anti-cancer drugs, even though the 
mucosal epithelia of the head and neck region are the primary 
sites of exposure to tobacco smoke. To the best of our knowl-
edge, the present study is the first to demonstrate the role of 
nicotine in metastasis and anti-EGFR-therapy resistance of 
HNSCC. The present findings demonstrated that nicotine 
increased proliferation, migration, invasion, p-EGFR nuclear 
translocation and protein kinase B (Akt) phosphorylation in 
HNSCC cells. It was also demonstrated that nicotine restored 
cetuximab-inhibited proliferation, migration and invasion of 
HNSCC cells. Finally, an in vivo experiment revealed that 
nicotine increased lymph node metastasis of xenografted 
tumors, whereas an nAChR inhibitor suppressed lymph node 
metastasis and p-EGFR nuclear localization of xenografted 
tumors. Taken together, these results demonstrated that nico-
tine induced nuclear accumulation of p-EGFR, and activation 
of Akt signaling. These signaling pathways elevated the 
activities of HNSCC cells, causing lymph node metastasis and 
serving a role in cetuximab resistance.
Introduction
Epidermal growth factor (EGF) was isolated from mouse 
submaxillary glands and demonstrated to promote incisor 
eruption and eyelid opening in newborn rodents (1). After 
EGF binds to its cell surface receptor (EGFR), EGFR 
undergoes dimerization, which in turn induces EGFR 
auto-phosphorylation (2). This auto-phosphorylation 
elicits downstream signal transduction cascades such as 
the phosphoinositide 3-kinase-pyruvate dehydrogenase 
kinase-protein kinase B (Akt) and RAF-mitogen-activated 
protein kinase kinase-extracellular signal-regulated kinase 
pathways, which promote cell survival and proliferation. 
Phosphorylated (p-)EGFR is translocated to the cytoplasm 
and degraded in lysosomes, which causes suppression of 
downstream signaling cascades in normal cells (2). However, 
in cancer cells, p-EGFR is accumulated in the nucleus, 
increasing cancer cell activity (3). EGFR is overexpressed in 
many cancers, including head and neck, breast, lung, colon, 
stomach, kidney, prostate and ovarian cancer, and is associated 
with worse outcome (4-6). An anti-EGFR monoclonal 
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antibody, cetuximab, is the first molecular target drug for head 
and neck squamous cell carcinoma (HNSCC) (7,8). When 
combined with radiotherapy and chemotherapy, cetuximab 
has been demonstrated to have significant survival benefits 
in patients with locally advanced and recurrent/metastatic 
HNSCC, respectively (7,8). However, resistance to cetuximab 
is known to develop gradually (9), and presents an important 
challenge for the future.
Tobacco smoking is associated with the carcinogenesis and 
development of cancer (10). Tobacco smoking is carcinogenic 
to the oral cavity, pharynx, larynx, esophagus, stomach, colon, 
liver, pancreas, lung, uterine cervix, ovary, kidney, renal pelvis 
and ureter, and bladder (10). The organs directly exposed to 
tobacco smoke are at high risk. Tobacco smoke is divided into 
a particle and gas phase (11). The particle phase includes tar 
and nicotine, while the gas phase includes carbon monoxide. 
Tar contains many carcinogenic chemicals, including benzo-
pyrene and nitrosamine. Nicotine is responsible for tobacco 
addiction, and thus nicotine replacement therapy, which 
supplies nicotine in the form of gum or a patch, is used to help 
individuals with tobacco addiction quit smoking (12).
The nicotine in the tobacco smoke is absorbed across the 
epithelium of the lung, and the mucosal epithelia in the head 
and neck region, e.g., the oral cavity, nasal cavity, pharynx, 
nasopharynx and larynx (13). Nicotine exerts its cellular func-
tions through nicotinic acetylcholine receptors (nAChRs). 
nAChRs are homomeric or heteromeric pentameric proteins 
consisting of α1-10, β1-4, γ, δ and ε subunits, and are located in 
the central nervous system and neuromuscular junctions (14). 
The binding of nicotine to nAChRs in the ventral tegmental 
area of the midbrain induces the release of dopamine to 
the nucleus accumbens, which is involved in the rewarding 
effects of nicotine and nicotine addiction. Although nAChR 
localization is thought to be limited in the nervous system, 
nAChR is present in a wide variety of non-neuronal cells, 
including bronchial epithelial, urothelial, skin, endothelial and 
vascular smooth muscle cells (15). The mucosal epithelia of 
the head and neck region are the primary sites of exposure to 
tobacco smoke, and nAChRs have been observed in mucosal 
epithelial cells in these regions (16,17). Previous studies have 
suggested that nAChRs are also present in lung cancer, breast 
cancer, pancreatic cancer, colon cancer and head and neck 
cancer cells (15,18-21). In lung and breast cancer, nicotine 
has been demonstrated to contribute to tumor growth and 
metastasis (19,20). Nicotine also controls the expression and 
subcellular localization of EGFR in breast cancer cells (22). 
Specifically, nicotine decreases the expression of EGFR, and 
enhances the accumulation of p-EGFR in the nucleus, thereby 
increasing proliferation of breast cancer cells (22). Finally, 
in lung cancer cells, nicotine serves a role in the resistance 
against EGFR inhibitors (23,24).
These facts prompted us to explore whether HNSCC 
cells could utilize nicotine-nAChR signaling to metastasize 
from the primary tumor to the regional lymph nodes and 
acquire resistance to cetuximab through EGFR activa-
tion. In the present study it was demonstrated that nicotine 
increased proliferation, migration, invasion, p-EGFR nuclear 
translocation and Akt activation in HNSCC cells. It was also 
demonstrated that nicotine restored cetuximab-inhibited 
proliferation, migration and invasion of HNSCC cells. Finally, 
it was demonstrated that an nAChR inhibitor suppressed 
lymph node metastasis in a mouse model of lymph node 
metastasis using OSC-19 cells.
Materials and methods
Cell culture and reagents. The following human HNSCC 
cell lines were used in the present experiments: HSC-2, a 
mouth floor SCC cell line derived from a metastatic cervical 
lymph node; HSC-3, a tongue SCC cell line derived from a 
metastatic cervical lymph node; OSC-19, a tongue SCC cell 
line derived from the primary site; and OSC-20, a tongue 
SCC cell line derived from a metastatic cervical lymph node. 
HSC-2 and HSC-3 were obtained from the Cell Engineering 
Division of the RIKEN BioResource Center (Ibaraki, 
Japan). OSC-19 and OSC-20 were obtained from the Health 
Science Research Resources Bank (Osaka, Japan). Human 
umbilical vein endothelial cells (HUVECs) were purchased 
from Takara Bio, Inc. (Otsu, Japan). All cancer cells were 
cultured in Dulbecco's modified Eagle's medium/Ham's 
F-12 nutrient mixture (DMEM/F-12: Gibco; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA) supplemented with 
10% fetal bovine serum (FBS: Sigma-Aldrich; Merck KGaA, 
Darmstadt, Germany) at 37˚C. HUVECs were cultured in 
endothelial cell growth medium‑2 (Takara Bio, Inc.) at 37˚C. 
Nicotine (Sigma-Aldrich; Merck KGaA; 0.5 µM) (19,20,22), 
mecamylamine hydrochloride (MCA; Sigma-Aldrich; Merck 
KGaA; 50 nM) (22), α-bungarotoxin (α-BTX; Abcam, 
Cambridge, UK; 1 µM) (17), cetuximab (Merck KGaA; 
0.5 µg/ml) (30), SCH772984 (Santa Cruz Biotechnology, Inc., 
Dallas, TX, USA; 1 µM) (25), Akt inhibitor II (Merck KGaA; 
10 µM) (26) and temsirolimus (Pfizer, Inc., New York, NY, 
USA; 10 nM) (27) were purchased. The concentration of nico-
tine (0.5 µM) used was decided based on previously published 
basic studies (19,20,22) and clinical investigations in which 
the concentrations of nicotine in the bloodstream of smokers 
exposed to nicotine at pharmacological concentrations were 
reported to be 0.09-1 µM (28,29).
Cell proliferation. Cells were seeded at a density of 1x105 cells 
in a 6‑well plate. After becoming subconfluent at 37˚C, the 
cells were cultured for 24 h in DMEM/F-12 without FBS. 
They were then cultured in the presence or absence of nicotine 
(0.5 µM) (19,20,22), MCA (50 nM) (22), α-BTX (1 µM) (17) or 
cetuximab (0.5 µg/ml) (30) in DMEM/F-12 supplemented with 
0.5% FBS. The number of cells was counted with TC10TM 
automated cell counter (Bio-Rad Laboratories, Inc., Hercules, 
CA, USA) daily for 5 days.
Invasion and migration assays. Invasion and migration of cells 
were studied as reported previously, by using Boyden cham-
bers with or without Matrigel®, respectively (BD Biosciences, 
Franklin Lakes, NJ, USA) (31). Cells in the logarithmic 
growth phase were detached by trypsin-EDTA, and 3x104 cells 
in serum-free DMEM/F12 were added to polycarbonate 
membranes (pore size, 8.0 µm). Nicotine (0.5 µM) was added 
to the lower chamber, and the system was incubated at 37˚C 
for 24 h in 5% CO2. Following incubation and fixation with 
70% ethanol for 10 min at room temperature, the non-invading 
or migrating cells were removed with a cotton swab and 
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the remaining cells were stained with 2% crystal violet 
(Sigma-Aldrich; Merck KGaA) for 5 min at room temperature. 
The number of stained cells on the lower side of the membrane 
in 4 light microscopic fields were counted, and the mean value 
of 3 wells was determined.
Immunoblot analysis. HSC-3 and OSC-19 cells were transferred 
to DMEM/F-12 without FBS, incubated for 24 h, and then 
treated with nicotine (0.5 µM) with or without MCA (50 nM), 
α-BTX (1 µM), cetuximab (0.5 µg/ml), SCH772984 (1 µM), Akt 
inhibitor II (10 µM) or temsirolimus (10 nM) at 37˚C for 1 h. Cells 
in monolayer cultures were rinsed with ice-cold PBS and lysed 
in an ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, containing 
150 mM NaCl, 1% Triton X-100, 1% NP-40, 10 mM NaF, 
100 mM leupeptin, 2 mg/ml aprotinin and 1 mM phenylmethyl 
sulfonyl fluoride). Protein concentration was determined using a 
BCA Protein Assay Kit (Pierce, Thermo Fisher Scientific, Inc.) 
The cell lysates containing 10 µg total protein in the lysis buffer 
were electrophoresed in 12% SDS-PAGE gels, and the proteins 
were then transferred to nylon membranes (Immobilon-P; 
EMD Millipore, Billerica, MA, USA). The membranes were 
blocked with 2% non‑fat dry milk in TBS overnight at 4˚C and 
then incubated with a 1:1,000 dilution of the desired antibody at 
4˚C for 12 h. Primary rabbit anti‑human p‑EGFR monoclonal 
immunoglobulin G (IgG; ab32578), mouse anti-human 
β-actin monoclonal IgG (ab49900), mouse anti-human PCNA 
monoclonal IgG (ab29; all Abcam), rabbit anti-human EGFR 
monoclonal IgG (4267S), rabbit anti-human p-Akt monoclonal 
IgG (4058), rabbit anti-human Akt monoclonal IgG (4685), 
rabbit anti-human p-mTOR polyclonal IgG (2974) and rabbit 
anti-human mTOR polyclonal IgG (2972; all Cell Signaling 
Technology, Danvers, MA, USA) were used for immunoblot 
analyses. Horseradish peroxidase (HRP)-conjugated goat 
anti-rabbit (RPN4301) or sheep anti-mouse IgG (NA931) 
were used as the secondary antibody at a 1:1,000 dilution 
(GE Healthcare Life Sciences, Little Chalfont, UK). Bands 
were visualized via enhanced chemiluminescence (RPN2109; 
GE Healthcare Life Sciences). Proteins in the nuclear and 
cytosolic fraction were obtained with NE-PERTM Nuclear and 
Cytoplasmic Extraction Reagents (Thermo Fisher Scientific, 
Inc.) using the experimental procedures specified by the 
manufacturer. For immunoblot analysis of α7 nAChR, the cell 
lysates containing 40 µg total protein in the lysis buffer were 
electrophoresed in 12% SDS-PAGE gels, and then the proteins 
were transferred to nylon membranes. The membranes were 
blocked with 2% non‑fat dry milk in TBS overnight at 4˚C 
and then incubated with a 1:400 dilution of rabbit anti-human 
α7 nAChR polyclonal IgG (ab10096; Abcam) overnight at 
4˚C. HRP‑conjugated goat anti‑rabbit IgG (RPN4301) was 
used as the secondary antibody at a 1:10,000 dilution (GE 
Healthcare Life Sciences). Band densities of immunoblotting 
were quantified with ImageJ (version 1.51; National Institutes 
of Health, Bethesda, MD, USA).
Immunofluorescence staining. Following growth on culture 
slides, cells were washed with PBS, fixed at ‑20˚C for 20 min 
with 100% methanol, and permeabilized with 0.1% NP-40 in 
PBS. The slides were blocked with 3% FBS in PBS for 10 min 
at room temperature. Following washing 3 times with PBS, the 
cells were incubated for 1 h with 1:50 dilution of anti-p-EGFR 
(rabbit IgG; ab32578; Abcam) in 3% BSA-PBS, washed 3 
additional times with PBS, and reacted with 1:1,000 dilution 
of Alexa Fluor 647 (Invitrogen; Thermo Fisher Scientific, Inc.) 
in 3% BSA‑PBS for 2 h at room temperature. Following a final 
wash, the cells were sealed with a coverslip and viewed under 
a fluorescent microscope (IX81; Olympus Corporation, Tokyo, 
Japan).
Lymph node metastasis model. All animal experiments 
were approved by the Institutional Animal Care and Use 
Committee of Okayama University (Okayama, Japan; 
OKU-2016046). The lymph node metastasis model was 
prepared as described previously (32). A total of 50 male 
athymic mice (nu/nu; age, 5 weeks; mean body weight, 
19.5 g) were obtained from CLEA Japan, Inc. (Tokyo, 
Japan). OSC-19 cells, 8x105 per mouse, were inoculated 
into a hind footpad. Groups of 10 mice each were peritone-
ally injected with either PBS, nicotine (30 µg/mouse) (20), 
MCA (20 µg/mouse) (33), nicotine and MCA, cetuximab 
(1 mg/mouse) (34), or cetuximab and nicotine every day. 
Tumor sizes and body weights were measured weekly, and 
the former were recorded in mm3 (length x width2 / 2). Mice 
were sacrificed at day 42, the footpad tumor tissues and 
popliteal lymph nodes were isolated and slides were prepared 
as described previously (32).
Immunohistochemistry for xenograft tumor specimens. 
Paraffin blocks of specimens were cut at 4‑µm thickness. 
The sections were deparaffinized, and then autoclaved 
in 0.2% citrate buffer for 15 min for antigen retrieval. 
Sections were incubated with 3% hydrogen peroxide for 
30 min at room temperature to block endogenous peroxi-
dase activity. Immunohistochemistry was performed using 
rabbit anti-human EGFR monoclonal IgG (Cell Signaling 
Technology, Inc.) and rabbit anti-human p-EGFR monoclonal 
IgG (Abcam), each at 1:100 dilution. The sections were 
incubated with the primary antibodies at 4˚C for 16 h, and 
then treated with Envision System Labeled Polymer (Dako; 
Agilent Technologies, Inc., Santa Clara, CA, USA) for 60 min 
at a dilution of 1:100. The immunoreaction was visualized 
using a 3,3'-diaminobenzidine substrate-chromogen solution. 
Finally, the sections were immersed in an ethanol and xylene 
bath and mounted for examination. The extent of p-EGFR 
staining was evaluated according to the percentage of cells 
with strongly stained nuclei in 3 visual fields under a light 
microscope (x200). All immunohistochemistry studies were 
evaluated by 2 experienced observers who were blind to the 
conditions of the experiments as reported previously (35).
Statistical analysis. Data were analyzed by using unpaired 
Student's t-test for analyses between two groups, and one-way 
analysis of variance with Bonferroni post hoc tests for the 
analysis of multiple group comparisons using SPSS statistical 
software (version 22; IBM Corp., Armonk, NY, USA). Results 
were expressed as the mean ± standard deviation. To control 
for multiple testing for data in the incidence of popliteal lymph 
node metastasis in mice, q-values were calculated with the false 
discovery rate method controlled by the Benjamini-Hochberg 
procedure. P<0.05 and q<0.05 were considered to indicate 
statistically significant differences.
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Results
Nicotine upregulated HNSCC cell proliferation. To examine 
the effect of nicotine in vitro, HNSCC cells were treated with 
0.5 µM nicotine for 5 days. This treatment stimulated a 2.4-, 1.6-, 
1.5- or 1.6-fold increase in the proliferation of HSC-2, HSC-3, 
OSC-19 and OSC-20 cells at day 5, respectively (Fig. 1A). 
Having established that nicotine stimulated the proliferation 
of HNSCC cells, whether nicotine receptors were expressed 
in HNSCC cells was then examined. Among nicotinic 
acetylcholine receptors, α7 nAChR has been reported as the 
primary receptor that mediates the proliferative effects of 
nicotine in various cancer cells (18). In the present study, it 
was demonstrated that all four HNSCC cell lines exhibited 
stronger α7 nAChR expression than that of the HUVEC used 
as the positive control for α7 nAChR (Fig. 1B).
nAChR inhibitors suppressed nicotine‑upregulated cell 
activities in HNSCC cells. As nicotine increased the cell 
proliferation of HNSCC cell lines, the effects of nAChR 
inhibitors on HNSCC cells were evaluated. As HSC-3 and 
OSC-19 have been reported to metastasize to the lymph 
nodes (36,37), it was decided to use these cell lines in later 
experiments. HSC-3 and OSC-19 were treated with MCA (a 
non-selective nAChR inhibitor) and α-BTX (an α7 nAChR 
inhibitor) in the presence of nicotine. Nicotine increased cell 
viability 1.3-fold in both HSC-3 and OSC-19 cells. MCA and 
α-BTX inhibited nicotine-induced viability to the same level 
as in the control group (Fig. 2A). In regard to cell migration, 
nicotine increased cell migration 1.4- and 1.2-fold in HSC-3 and 
OSC-19 cells, respectively, and MCA and α-BTX suppressed 
these nicotine-induced effects (Fig. 2B). Finally, invasion of 
HSC-3 and OSC-19 cells was increased 1.4- and 1.3-fold by 
nicotine, respectively, and MCA and α-BTX counteracted 
these effects as well (Fig. 2C).
Nicotine induced phosphorylation and nuclear translocation 
of EGFR. EGFR is known to be overexpressed and its 
signaling pathway is one of the most important pathways in 
HNSCC (3). As nicotine upregulated the cell activities of 
Figure 1. Effects of nicotine on the cell proliferation and expression of α7 nAChR of head and neck squamous cell carcinoma cells. (A) Proliferation. Cells were 
seeded at a density of 1x105 cells in a 6-well plate. After cells were attached to the plate, they were starved for 24 h in DMEM/F-12 without FBS. They were 
then cultured in the presence or absence of nicotine in DMEM/F-12 supplemented with 0.5% FBS. All experiments were repeated 3 times. (B) Expression of 
α7 nAChR in HSC-2, HSC-3, OSC-19 and OSC-20 cells. HUVECs were used as a positive control of α7 nAChR. Data are presented as the mean ± standard 
deviation of triplicates from a typical experiment. *P<0.05. nAChR, nicotinic acetylcholine receptor; DMEM/F‑12, Dulbecco's modified Eagle's medium/Ham's 
F-12 nutrient mixture; FBS, fetal bovine serum; HUVEC, human umbilical vein endothelial cell.
INTERNATIONAL JOURNAL OF ONCOLOGY  54:  283-294,  2019 287
HNSCC in the present experiments, the effect of nicotine 
on EGFR activation was evaluated. It was demonstrated that 
both EGFR phosphorylation and Akt phosphorylation were 
increased 1 h following the addition of nicotine (Fig. 3A). 
Immunofluorescence analysis of HNSCC cells demonstrated 
that nicotine induced p-EGFR nuclear translocation (Fig. 3B). 
To obtain quantitative data on this effect, p-EGFR distribution 
was evaluated in the nuclear and cytosolic fractions. 
Immunoblot analysis revealed an increase in nuclear p-EGFR 
in both HSC-3 (7.1-fold p-EGFR/EGFR and 1.4-fold p-EGFR/
β-actin) and OSC-19 (2.2-fold p-EGFR/EGFR and 1.6-fold 
p-EGFR/β-actin) cells exposed to nicotine, respectively 
(Fig. 3C).
Nicotine induced phosphorylation of EGFR, Akt and mTOR 
through nAChRs. To determine whether nAChRs served any 
role in the activation of EGFR and Akt by nicotine, whether 
nAChR inhibitors would suppress the effects of nicotine 
Figure 2. Effects of nAChR inhibitors on the cell viability, migration and invasion of HNSCC cells. (A) Viability. Cells were seeded at a density of 1x105 cells 
in a 6‑well plate. After becoming subconfluent, cells were cultured for 24 h in DMEM/F‑12 without FBS. They were then cultured in the presence or absence 
of nicotine, MCA or α-BTX in DMEM/F-12 supplemented with 0.5% FBS. The cell number was measured at day 5. (B) Migration. Migration was evaluated 
using Boyden chambers. Cells were seeded at a density of 3x104 in medium with or without MCA, α-BTX or cetuximab on polycarbonate membranes. Nicotine 
was added to the lower chamber, and the system was incubated for 24 h. Following incubation, the number of cells on the lower side of the membrane was 
counted. (C) Invasion. Invasion was evaluated using Boyden chambers with Matrigel®. Incubation and cell counting were performed as in the migration assay. 
All experiments were repeated 3 times. Data are presented as the mean ± standard deviation of triplicates from a typical experiment. *P<0.05. nAChR, nicotinic 
acetylcholine receptor; HNSCC, head and neck squamous cell carcinoma; DMEM/F‑12, Dulbecco's modified Eagle's medium/Ham's F‑12 nutrient mixture; 
FBS, fetal bovine serum; MCA, mecamylamine hydrochloride; α-BTX, α-bungarotoxin.
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Figure 3. Effect of nicotine on EGFR and Akt activation in head and neck squamous cell carcinoma cells. (A) HSC-3 and OSC-19 cells were treated with 
0.5 µM nicotine for the indicated times, and cell layer extracts were then analyzed by immunoblotting with antibodies recognizing p-EGFR and p-Akt. 
(B) Cells were immunostained for the intracellular distribution analysis of p-EGFR in untreated and nicotine-treated cells. Nicotine induced p-EGFR nuclear 
translocation in both HSC-3 and OSC-19 cells. DAPI was used for nuclear staining. Scale bar, 200 µm. The merged, p-EGFR and DAPI images were merged. 
The insert presents high magnification images of the indicated areas of p‑EGFR or merged. Scale bar, 30 µm. (C) Harvest cells were sub‑fractionated into 
cytoplasmic and nuclear fractions and processed for immunoblot analysis of p-EGFR. β-actin and PCNA were loading controls. Bar charts present the relative 
protein levels of p-EGFR/EGFR and p-EGFR/β-actin in HSC-3 and OSC-19 cells. Data are presented as the mean ± standard deviation. *P<0.05. EGFR, 
epidermal growth factor receptor; Akt, protein kinase B; p, phosphorylated.
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was evaluated. Treatment with MCA and α-BTX reversed 
the nicotine-induced activation of EGFR and Akt (Fig. 4A), 
suggesting that nicotine activates EGFR and Akt via nAChRs. 
To examine whether Akt and mTOR are involved in the region 
downstream of the nicotine-nAChR-EGFR pathway, Akt 
inhibitor II (an Akt inhibitor) and temsirolimus (an mTOR 
inhibitor) were used. Treatment with Akt inhibitor II reversed 
the nicotine-dependent stimulation of Akt and mTOR, whereas 
it did not change EGFR phosphorylation (Fig. 4B). In a 
similar manner, temsirolimus also markedly counteracted the 
nicotine-dependent stimulation of mTOR, whereas it did not 
change the levels of EGFR or Akt phosphorylation (Fig. 4B). 
SCH772984 (a MAPK inhibitor) did not change EGFR, Akt or 
mTOR phosphorylation (Fig. 4B). Taken together, our findings 
demonstrate that nicotine stimulated the EGFR-Akt-mTOR 
signaling pathway via nAChRs in HNSCC cells.
Notably, in lanes 5 and 6 of Fig. 4A, it was observed that 
nicotine upregulated cetuximab-suppressed EGFR phosphor-
ylation, suggesting that nicotine may contribute to cetuximab 
resistance.
Nicotine counteracted the anti‑tumor effects of cetuximab in 
HNSCC cells. As nicotine upregulated cetuximab-suppressed 
EGFR phosphorylation, it was speculated that nicotine coun-
teracted anti-EGFR therapy through EGFR activation. To test 
this hypothesis, HNSCC cells were treated with cetuximab 
and nicotine, then the cell activities were evaluated.
In the presence of cetuximab alone, the proliferation of 
HSC‑3 and OSC‑19 cells was significantly inhibited. When 
nicotine was added, however, the proliferation of both HSC-3 
and OSC-19 cells increased to 1.4-fold of that in the group 
treated with cetuximab alone (Fig. 5A). Cetuximab also signif-
icantly inhibited the cell migration of HNSCC cells. However, 
when nicotine was added, the cell migrations of HSC-3 and 
OSC-19 cells were increased to 1.7- and 1.3-fold of those in 
the cells treated with cetuximab alone (Fig. 5B). In a similar 
manner, the levels of invasion of HSC-3 and OSC-19 cells 
treated with cetuximab and nicotine were 1.9- and 1.6-fold of 
those in the cells treated with cetuximab alone, respectively.
An nAChR inhibitor suppressed the tumor growth and lymph 
node metastasis of xenografted HNSCC in athymic mice. 
To further investigate whether nicotine was responsible for 
tumor growth and metastasis by HNSCC cells, an animal 
model of lymph node metastasis was utilized (32). To inhibit 
nAChRs, only MCA was used in animal experiments. 
Figure 4. Effects of MCA, α-BTX, cetuximab, SCH772984, Akt inhibitor II and temsirolimus on nicotine-dependent activation of EGFR, Akt and mTOR 
in head and neck squamous cell carcinoma cells. (A) Nicotinic acetylcholine receptor; downstream signaling. HSC-3 and OSC-19 cells were transferred to 
DMEM/F-12 without FBS, incubated for 24 h, and then treated with 0.5 µM nicotine with or without MCA, α-BTX or cetuximab for 1 h. Protein extracts 
were analyzed by immunoblotting with antibodies recognizing p-EGFR and p-Akt. (B) EGFR downstream signaling. Cancer cells were transferred to 
DMEM/F‑12 without FBS, incubated for 24 h, and then treated with nicotine with or without SCH772984, Akt inhibitor II or temsirolimus at 37˚C for 1 h. 
Protein extracts were analyzed by immunoblotting with antibodies recognizing p-EGFR, p-Akt and p-mTOR. MCA, mecamylamine hydrochloride; α-BTX, 
α-bungarotoxin; EGFR, epidermal growth factor receptor; Akt, protein kinase B; mTOR, mechanistic target of rapamycin; DMEM/F‑12, Dulbecco's modified 
Eagle's medium/Ham's F-12 nutrient mixture; FBS, fetal bovine serum; p, phosphorylated.
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MCA (38) is well-known as an antihypertensive drug under 
the name Inversine® (39), whereas α-BTX is famous as a snake 
venom (40); therefore, MCA was speculated to be more suit-
able for future clinical application.
In the animal experiments, nicotine increased the growth 
rate of xenografted tumors compared with the rate in the 
control group, and MCA decreased tumor growth compared 
with the nicotine-treated group (Fig. 6A). The tumor volumes 
at the end of the experiment (day 42) for the control group, 
nicotine-treated group and MCA group were 615.2±65.3, 
950.0±188.9 and 686.5±156.4 mm3, respectively. These results 
indicated an ~54.5% increase in the tumor growth rate for 
the nicotine‑treated group. The findings also suggested that 
MCA effectively inhibited the nicotine-induced xenograft 
tumor growth of HNSCC cells in athymic mice to the same 
level as in the control group (Fig. 6A). Furthermore, nicotine 
increased cetuximab-suppressed xenografted tumor growth 
from 1.2±1.8 to 32.9±37.7 mm3, suggesting that nicotine may 
contribute to local relapse following anti-EGFR therapy.
To determine whether nicotine influences p‑EGFR local-
ization in vivo, the percentage of p-EGFR-positive nuclei in 
the tumor specimens was evaluated. As presented in Fig. 6B, 
the percentage of p-EGFR-positive nuclei was increased in 
the nicotine-treated group (57.7±8.4%) compared with the 
control group (42.6±9.9%), which was consistent with the 
in vitro analysis. Conversely, MCA decreased the percentage 
of p-EGFR-positive nuclei to the level of the control group 
(46.8±9.6%). Nicotine also increased the rate of popliteal lymph 
Figure 5. Effects of nicotine on cetuximab-suppressed viability, migration and invasion of head and neck squamous cell carcinoma cells. (A) Viability. 
Cells were seeded at a density of 1x105 cells in a 6‑well plate. After becoming subconfluent, cells were cultured for 24 h in Dulbecco's modified Eagle's 
medium/Ham's F-12 nutrient mixture without fetal bovine serum. They were treated with cetuximab for 30 min, and then cultured in the presence or absence 
of nicotine. The cell number was measured at day 6. (B) Migration. Migration was evaluated using Boyden chambers. Cells were seeded at a density of 3x104 in 
medium with cetuximab on polycarbonate membranes. Nicotine was added to the lower chamber, and the system was incubated for 24 h. Following incubation, 
the number of cells on the lower side of the membrane was counted. (C) Invasion. Invasion was evaluated using Boyden chambers with Matrigel®. Incubation 
and cell counting were performed as in the migration assay. All experiments were repeated 3 times. Data are presented as the mean ± standard deviation of 
triplicates from a typical experiment. *P<0.05.
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node metastasis from 10 to 60%. MCA decreased the rate of 
metastasis to 20%. Although there were no significant differ-
ences between the any two groups, there was a trend toward 
higher metastasis rate with nicotine compared with control. 
(control vs. nicotine, q=0.057; nicotine vs. nicotine+MCA, 
q=0.159; nicotine+MCA vs. control, q=1.593; Fig. 6C). There 
was no lymph node metastasis in either the cetuximab-treated 
group or the cetuximab and nicotine-treated group.
Taken together, the in vivo experiments revealed 
that nicotine increased the tumor growth and lymph 
node metastasis of HNSCC, whereas MCA suppressed 
them. It was also demonstrated that nicotine restored the 
cetuximab-inhibited tumor growth of HNSCC. The activation 
and nuclear localization of EGFR may contribute to these 
tumor-promoting effects of nicotine.
Discussion
Nicotine, one of the crucial components in the addictiveness 
of tobacco, also has important roles in the invasion and metas-
tasis of various cancers, including lung cancer, breast cancer, 
glioma, bladder cancer, pheochromocytoma and colorectal 
cancer (15,18). In lung cancer cells, nicotine exposure induces 
epithelial-mesenchymal transition (41). In breast cancer cells, 
nicotine promotes cell motility via PKC and cdc42, leading 
to lung metastasis (20). However, its effect in HNSCC cells 
is unknown. To determine whether nicotine influences 
HNSCC in vivo, a mouse model of lymphatic metastasis was 
prepared (32). In this model, nicotine increased the tumor 
volume and incidence of metastasis in regional lymph nodes 
compared with the control groups. Consistent with the in vivo 
Figure 6. Effect of nicotine, MCA and cetuximab on the growth of OSC-19 xenografts and lymph node metastasis in athymic mice. (A) A total of 8x105 OSC-19 
cells per mouse (10 mice/group) were inoculated into the hind footpad of athymic mice. Mice were peritoneally administered with PBS, nicotine (30 µg/mouse), 
MCA (20 µg/mouse), nicotine and MCA, cetuximab (1 mg/mouse), or cetuximab and nicotine every day. Mice were sacrificed at day 42. In bar chart, the 
data are presented as tumor volume in mm3 (length x width2 / 2). Data are presented as the mean ± standard deviation. *P<0.05. (B) IHC staining of OSC-19 
xenograft tumor specimens from the hind footpad. IHC staining of EGFR and p-EGFR in tumors from the OSC-19 treated with or without nicotine or MCA is 
presented. Nicotine induced nuclear localization of p-EGFR (arrows) whereas MCA suppressed nicotine-induced nuclear localization of p-EGFR. Scale bar, 
100 µm. (C) The rate of popliteal lymph node metastasis is presented as the number of mice with metastases/number of mice injected. Lymph node metastasis 
was observed in the control group (10%), nicotine-treated group (60%) and nicotine and MCA-treated group (20%). MCA, mecamylamine hydrochloride; 
IHC, immunohistochemical; EGFR, epidermal growth factor receptor; p, phosphorylated.
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experiments, in in vitro studies, cell proliferation, migration 
and invasion were significantly elevated in the nicotine‑treated 
groups than the control groups in all four HNSCC cell lines. 
In the animal model, nicotine failed to induce lymphangio-
genesis in tumor tissues (data not shown). This suggests that 
nicotine-induced lymphatic metastasis was attributable to 
nicotine-driven invasive cell activities. Conversely, MCA and 
α-BTX, two nAChR inhibitors, reversed the nicotine-driven 
invasive cell activities, suggesting that nicotine stimulation 
of cell activities occurs through nAChRs. The head and 
neck mucous epithelia express α3, α5, α7, α9, β2 and β4 
nAChRs (16,17). Among these nAChR subunits, α7 has been 
implicated as the most powerful nAChR subunit in terms 
of mediating the proliferative effects of nicotine in various 
cancer cells (18). Furthermore, nicotine activates α7 nAChR 
of keratinocytes in the head and neck region (17,42,43). These 
findings indicate that nicotine accelerates cell activity of 
HNSCC cells via α7 nAChR. This is consistent with the present 
in vitro finding that α-BTX inhibited nicotine-increased cell 
proliferation, migration and invasion to the level of the control 
groups.
Cetuximab, a chimeric human mouse anti-EGFR mono-
clonal antibody, was the first molecular target drug used in 
head and neck cancer therapy (7,8). In our experiments, 
nicotine induced phosphorylation and nuclear translocation 
of EGFR. Nuclear translocation of EGFR is correlated with 
worse prognosis of HNSCC (3). Cetuximab is known to 
inhibit EGFR translocation to the nucleus, while accumula-
tion of intranuclear EGFR is known to have some relevance 
to cetuximab resistance (3). Nicotine may suppress the 
anti-tumor effect of cetuximab by promoting EGFR nuclear 
translocation. In the present experiments, nicotine restored the 
cetuximab-inhibited cell proliferation, migration and inva-
sion of HNSCC cells. However, we note here that cetuximab 
resistance might also arise through another mechanism, since 
nicotine failed to restore the cetuximab-inhibited cell activi-
ties to the level seen in the untreated control groups.
In the in vitro experiments, cetuximab inhibited EGFR 
phosphorylation in HSC-3 cells. Conversely, cetuximab 
increased EGFR phosphorylation in OSC-19 cells, although 
Akt phosphorylation was still inhibited by cetuximab in 
this cell line. Recently, it was demonstrated that HNSCC 
secreted cetuximab with EGFR-containing extracellular vesi-
cles (44,45). OSC-19 cells may incorporate cetuximab-bound 
EGFR in the cytoplasm following EGFR phosphorylation, and 
the cetuximab-bound EGFR may be excluded by this novel 
mechanism.
To date, no study has examined the direct effect of 
nicotine on cetuximab sensitivity, to the best of our knowl-
edge. However, a few studies have demonstrated the effect 
of nicotine on anti-EGFR cancer therapy. In non-small cell 
lung cancer, nicotine induces resistance to erlotinib and 
gefitinib, which are EGFR tyrosine kinase inhibitors (23,46). 
In colorectal cancer, cigarette smoking during anticancer 
treatment with a cetuximab-based regimen reduces the 
therapeutic benefit (47). These findings support the present 
hypothesis that nicotine serves a role in cetuximab resis-
tance. In addition, nicotine suppresses cisplatin-induced 
apoptosis in HNSCC cells through Akt signaling, which is a 
mandatory signaling pathway for cell survival and regulation 
Figure 7. Function of nicotine in EGFR signaling in HNSCC. Nicotine binds to nAChR and enhances EGFR phosphorylation in HNSCC cells. EGFR 
phosphorylation elicits the Akt-mTOR pathway, a downstream signal transduction cascade, and p-EGFR itself is translocated to the nucleus, leading 
to cell proliferation, migration, invasion and cetuximab resistance. EGFR, epidermal growth factor receptor; HNSCC, head and neck squamous cell 
carcinoma cells; nAChR, nicotinic acetylcholine receptor; Akt, protein kinase B; mTOR, mechanistic target of rapamycin; EGF, epidermal growth factor; 
P, phosphate group.
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of apoptosis (48). Akt regulates the expression of survivin, 
which inhibits apoptosis (48). In the present experiments, 
nicotine treatment induced phosphorylation of Akt and its 
downstream molecule mTOR. This suggests that MCA and 
α-BTX inhibited Akt phosphorylation and that nicotine 
induced Akt phosphorylation through nAChRs. Furthermore. 
Akt inhibitor II and temsirolimus induced no changes in the 
expression or phosphorylation of EGFR, suggesting that the 
nicotine-driven Akt phosphorylation resides downstream of 
EGFR (Fig. 7).
In an in vivo experiment, cetuximab inhibited metastasis. 
However, nicotine failed to restore the cetuximab-inhibited 
metastasis. Therefore, the effect of nicotine in metastatic 
HNSCC treated with cetuximab remains unclear, and further 
investigation of this effect is required. In human papillo-
mavirus-positive oropharyngeal cancer, increased distant 
metastases rates were noted in active smokers vs. never/former 
smokers (22 vs. 5%), and cetuximab-based bio-radio-
therapy (BRT) vs. cisplatin-based chemoradiotherapy (CRT) 
(23 vs. 5%) (49). Although there was no difference in nodal 
disease extent between CRT and BRT groups in that previous 
study, nicotine and cetuximab may have synergistic negative 
effects in certain types of HNSCC.
In conclusion, nicotine induced the phosphorylation 
of EGFR through nAChR in the present experiments. 
Phosphorylated EGFR was translocated from the cell surface 
to the nucleus, and activated Akt and mTOR. These signaling 
pathways elevated the cell activities of HNSCC cells, causing 
lymph node metastasis and serving a role in cetuximab resis-
tance (Fig. 7). Blockade of nicotine-nAChR signaling may be 
of clinical benefit in cases of advanced HNSCC, especially 
HNSCC in the oral cavity, which is the primary site of expo-
sure to nicotine, by inhibiting lymph node metastasis and 
releasing cetuximab resistance.
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